Systemic Lupus Erythematosus
An Introduction to Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic, heterogeneous, multisystem autoimmune disease characterised by severe fatigue and joint pain. Traditional treatment strategies have involved hydroxychloroquine, systemic glucocorticosteroids and conventional immunosuppressive drugs, but are associated with severe toxicities. Many current and emerging therapeutic strategies target B-cell-surface antigen, B-cell survival factors or B-cell intracellular signalling. However, many of these have disappointed in clinical trials, and there remains a need for new strategies. Novel therapies targeting interferons, cytokines and their receptors, intracellular signals, plasma cells, T lymphocytes and co-stimulatory molecules are also being investigated.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Systemic Lupus Erythematosus Content
Ronald Van Vollenhoven, EULAR 2021: The 2021 DORIS Definition of Remission in SLE
TouchIMMUNOLOGY got the opportunity to catch up with Professor Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss the final recommendations from the DORIS taskforce in defining remission in systemic lupus erythematosus. The abstract ‘The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force.‘ (OP0296), was presented at the […]
Ronald Van Vollenhoven, EULAR 2021: Challenges in Defining Remission in SLE
TouchIMMUNOLOGY got the opportunity to catch up with Prof. Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss the final recommendations from the DORIS taskforce in defining remission in systemic lupus erythematosus. The abstract ‘The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force.‘ (OP0296), was presented at the […]
Joan Merrill, EULAR 2021: Findings from the TULIP-1 and TULIP-2 Trials
TouchIMMUNOLOGY were delighted to talk with Dr Joan Merrill (University of Oklahoma Health Sciences Center, Oklahoma City, OK, US) around the use of anifrolumab in the treatment of rash and arthritis in patients with SLE and the impact of IFN gene signatures on treatment response. The abstract ‘Anifrolumab Effects on Rash and Arthritis in Patients […]
Richard Furie, ACR 2020 – NKTR-358 in Patients with Systemic Lupus Erythematosus
Following his presentation at ACR 2020, we spoke with Richard Furie (Northwell Health Zucker School of Medicine at Hofstra/Northwell, NY, USA) about the novel IL-2 conjugate, NKTR-358 in patients with systemic lupus erythematosus (Clinical Trial Identifier: NCT03556007). The abstract ‘Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 […]
Ronald van Vollenhoven, ACR 2020 – Ustekinumab in the Treatment of Systemic Lupus Erythematosus
We caught up with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) to discuss the use of ustekinumab in patients with active systemic lupus erythematosus (Clinical Trial Identifier: NCT02349061). The abstract ‘Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!